On the other hand, SERCA inhibitors such as thapsigargin [129] or 2,5-di-tert-butyl-1,4-benzohydroquinone [130] are known tumor promoters in vivo, and mutations in SERCA2, as well as SERCA3 sequences have been found in several human tumor types [131,132,133]. The gene discussed is ATP2A2; the disease is neoplasm.